Key facts
- An FDA advisory committee will meet July 23-24 to discuss easing restrictions on seven research peptides.
- These peptides are currently banned for compounding pharmacy production due to safety concerns.
- Proponents argue easing restrictions would provide a safer supply than the current gray market.
- Critics highlight the lack of robust safety and efficacy data for these substances.
- A decision to ease restrictions could significantly boost revenue for telehealth companies like Hims & Hers.
Advisers to the Food and Drug Administration (FDA) are scheduled to meet on July 23-24 to discuss potentially easing restrictions on access to seven research peptides. These injectable drugs, which include substances like BPC-157 and Semax, have gained popularity as wellness aids despite limited scientific evidence of their safety and efficacy in humans. A decision to ease restrictions could allow US compounding pharmacies to legally produce and prescribe these peptides, effectively legalizing a gray market that has thrived since a 2023 ban. The ban, implemented by the Biden administration, cited serious safety concerns such as priapism and potential tumor growth. Proponents, including some patients and compounding pharmacies, argue that easing restrictions would provide a safer, regulated supply compared to the current unregulated online market. However, many physicians and public health advocates, like Dr. Eric Topol, express strong opposition, emphasizing the lack of data and potential risks. Telehealth companies, such as Hims & Hers, stand to gain significantly from a regulatory shift, with analysts estimating a substantial market share for such services. The FDA is not obligated to follow the committee's advice but typically does. The discussion does not equate to FDA approval, which requires rigorous clinical trials.
=== ADDITIONAL SOURCE ===
Robert F. Kennedy Jr., characterizing the Biden administration's ban on research peptides as 'illegal,' has expressed support for these substances, stating he is a 'big fan' and has used them himself. Critics, however, draw parallels to Kennedy's past actions regarding vaccine advisory committees, suggesting a potential for predetermined outcomes regardless of evidence. The potential market for telehealth peptide prescribing is estimated to reach $2.2 billion annually, with Hims & Hers potentially capturing a significant portion. Hims & Hers acquired a US-based peptide facility in 2025 and has publicly supported the FDA's re-evaluation of these drugs' status. Dr. Anant Vinjamoori of Hims & Hers noted that while evidence is largely preclinical, 'preclinical evidence isn’t no evidence.'